Pharmafile Logo

News and Press Releases

Kite’s CAR T-Cell Therapy YESCARTA (Axicabtagene Ciloleucel) Compared with Bispecifics in R/R DLBCL in Two Analyses at ESMO 2023

23 October 2023 -- Stockley Park, UK -- Kite, a Gilead Company, today announced results from two indirect comparative analyses of its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) versus bispecific...

Category: Clinical Trials
Posted: October 23, 2023

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Mundipharma and Cidara Therapeutics receive positive CHMP opinion forrezafungin for the treatment of Invasive Candidiasis in adults

The opinion was based on positive results from the pivotal ReSTORE phase 3 clinicaltrial and supported by the STRIVE phase 2 clinical trials and extensive nonclinicaldevelopment programme If approved by...

Category: Biotechnology
Posted: October 17, 2023

Cidara Therapeutics
info@cidara.com
6310 Nancy Ridge Drive Suite 101 San Diego, CA 92121

Gilead and Kite Oncology  Present Important Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

– Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy (sacituzumab govitecan-hziy) in Metastatic Breast Cancers – New Data Demonstrate Potential of Sacituzumab Govitecan in Small Cell Lung...

Category: Pharmaceutical
Posted: October 16, 2023

Gilead Sciences, Inc

Kite’s CAR T-Cell Therapy Accepted for Use on the NHS in Scotland to Treat Aggressive Form of Blood Cancer

First CAR T-cell therapy for adult (26+) patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) reimbursed in Scotland 9 October 2023 -- London, UK -- Gilead Sciences...

Category: Pharmaceutical
Posted: October 9, 2023

Gilead Sciences, Inc